CJC/IPA Protocol
GHRH/GHRP Combination | Growth Hormone Optimization
A dual-pathway protocol combining CJC-1295 and Ipamorelin that targets growth hormone secretion through complementary mechanisms. CJC-1295 demonstrates 2-10 fold GH increases with 6-8 day duration, while Ipamorelin provides selective GH release without cortisol elevation.
Mechanism of Action
CJC-1295 activates GHRH receptors via albumin-binding DAC technology for sustained elevation. Ipamorelin selectively activates ghrelin receptors (GHSR1a) without affecting ACTH/cortisol, preserving natural pulsatile GH patterns.
Key Benefits
- Sustained GH elevation (6-8 days from CJC-1295)
- Selective pulsatile release without cortisol suppression
- Complementary dual-pathway optimization
- Preservation of natural GH rhythm
- Enhanced muscle protein synthesis and recovery
N/A Complex or non-standard sequence format
Muscle Growth
- Enhanced Protein Synthesis
Growth hormone elevation supports muscle protein synthesis and nitrogen retention during training.
- Improved Recovery
Sustained GH patterns may accelerate muscle repair between exercise sessions.
- Lean Mass Preservation
GH optimization helps maintain muscle during caloric restriction or aging.
Metabolic Health
- Body Composition Support
Growth hormone promotes lipolysis while supporting lean tissue maintenance.
- Metabolic Flexibility
Enhanced GH patterns may improve glucose and fat utilization.
Anti-Aging
- Sleep Quality Enhancement
Evening GH peaks align with deeper, more restorative sleep patterns.
- Tissue Regeneration
Sustained GH elevation supports skin elasticity and connective tissue health.
Recovery
- Accelerated Healing
Growth hormone supports tissue repair and recovery from exercise or injury.
- Joint Health
Enhanced collagen synthesis supports joint and connective tissue integrity.
Subcutaneous administration optimal for bioavailability; available as blended vials or separate formulations.
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| General Health Optimization | 200mcg each (0.2mL if 1mg/mL) | Once daily | SubQ |
| Performance Enhancement | 250mcg each (0.25mL if 1mg/mL) | Once daily | SubQ |
| Recovery Optimization | 300mcg each (0.3mL if 1mg/mL) | Once daily | SubQ |
| Conservative Approach | 150mcg each (0.15mL if 1mg/mL) | 5 days per week | SubQ |
Reconstitution Instructions
- Bacteriostatic water (2-4mL)
- Insulin syringes (0.3-1mL capacity)
- Alcohol swabs for sterilization
- 1 BLENDED: Add 2mL bacteriostatic water to create ~2mg/mL concentration
- 2 SEPARATE: Add 2mL water to each vial for 1mg/mL per peptide
- 3 Draw 0.2-0.3mL for 200-300mcg dosing
- 4 Mix equal volumes or inject at different sites
- 5 Administer 2-3 hours post-meal, 30-60 minutes before bed
- 6 Rotate subcutaneous sites (abdomen, thigh, upper arm) daily
Both affect GH pathways; monitor for excessive GH elevation and insulin sensitivity changes.
No known interactions; different mechanisms (GH optimization vs. tissue repair signaling).
GH affects insulin sensitivity; diabetic users require glucose monitoring and insulin adjustments.
Redundant mechanisms may cause excessive GH suppression of natural pulsatile release.
Space 4+ hours from GH secretagogues due to absorption and metabolic interactions.
May blunt GH response; higher doses or alternative timing may be necessary.
Improved sleep depth and quality; increased dream vividness
Enhanced exercise recovery; reduced muscle soreness; improved energy
Gradual body composition changes; improved skin quality; general well-being
Optimized benefits plateau; individual responses vary significantly
Benefits persist several weeks due to improved sleep and recovery patterns
Common Side Effects
- Water retention and joint swelling
- Carpal tunnel syndrome (numbness/tingling)
- Mild blood glucose elevation
- Injection site irritation with improper rotation
Stop Signs - Discontinue if:
- Persistent joint pain or swelling indicating fluid retention
- Significant blood glucose changes or diabetic control issues
- Unusual fatigue, lethargy, or mood deterioration
- Injection site infections or persistent reactions
- Numbness or tingling in hands/feet
- Signs of accelerated tumor growth if cancer history exists
Contraindications
- Cancer history or active malignancy
- Severe diabetes requiring tight glucose control
- Carpal tunnel syndrome or nerve compression disorders
Good Signs
- Standard format labeling: '10mg total: 5mg CJC-1295 + 5mg Ipamorelin'
- 1:1 ratio maintenance between peptides for optimal effects
- Clear reconstitution without particles or cloudiness
- Certificate of Analysis with individual peptide purities
- Proper cold chain with cold packs and immediate refrigeration
Warning Signs
- Format selection: Beginners prefer separate vials for tolerance testing
- Blended format offers convenience but limits dose adjustment
- Combination protocols lack peer-reviewed clinical validation
Bad Signs
- Damaged packaging or missing refrigeration
- Heat exposure during shipping
- Lack of Certificate of Analysis documentation
- CJC-1295 Clinical Efficacy - Teichman et al.(2006)
2-10 fold GH increase, 1.5-3 fold IGF-1 increase with 5.8-8.1 day half-life.
- Ipamorelin Selectivity - Raun et al.(1998)
First selective GHS with no ACTH/cortisol effects even at 200x effective dose.
- GH Pulsatility Preservation - Ionescu & Frohman(2006)
CJC-1295 preserves pulsatile GH secretion while increasing basal levels 7.5-fold.
- GHRH-GHS Receptor Interaction - Cunha & Mayo(2002)
Cellular study demonstrating potentiation of GHRH signaling with GHS receptors present.
Disclaimer
This information is for educational and research purposes only. Consult a healthcare professional before use.